

U.S. NUCLEAR REGULATORY COMMISSION

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

*OC 02120*

*217357*

Licensee

In accordance with letter dated  
**July 9, 2008,**

- 1. **St. Elizabeth Regional Health  
d/b/a Greater Lafayette Health Services, Inc.**  
Nuclear Medicine Department
- 2. 2400 South Street  
Lafayette, IN 47904-3027

3. License number 13-09788-01 is amended in its entirety to read as follows:

4. Expiration date **November 30, 2013**

5. Docket No. 030-01642  
Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed 1 curie of iodine-131)
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed sources ( Mills Biopharmaceuticals Model I-125 SL & SH; Best Industries Model 2300 series; Theragenics Model 200; Nuclear Enterprises Model 2503/3; IAI-125A (Advantage™ I-125))	D. One curie
E. Any byproduct material permitted by 10 CFR 35.500	E. Sealed sources (North American Scientific, Inc. Model MED 3601, Du Pont Merck Pharmaceutical Company Model NES-8412 or Isotopes Products Laboratories, Inc. Model A3410)	E. 0.3 curies per source and 2 curies total

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
13-09788-01

Docket or Reference Number  
030-01642

Amendment No. 59

9. Authorized Use:

- A. Any uptake, dilution and excretion study permitted by 10CFR 35.100.
- B. Any imaging and localization study permitted by 10CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).

CONDITIONS

- 10. Licensed material listed in Subitems 6.A. through 6.E. shall be used at the licensee's facilities located at Lafayette Home Hospital, 2400 South Street, Lafayette, Indiana and St. Elizabeth Medical Center, 1501 Hartford Street, Lafayette, Indiana.
- 11. The Radiation Safety Officer is Paul E. Gandy, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for the materials and uses indicated:

Authorized Users

Material and Use

David R. Schmidt, M.D.	10 CFR 35.200 and 35.500.
Adel Yaacoub, M.D.	10 CFR 35.200 and 35.500.
Irene C. Gordon, M.D.	10 CFR 35.300, 35.400 and 35.500.
Debbie Wright, M.D.	10 CFR 35.200 and 35.500.
Robert Mehl, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to sodium iodide I131) and 35.500.
John F. Fiederlein, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Steven B. Jones, M.D.	10 CFR 35.100, 35.200, and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries), and 35.500.
Sam Hansen, M.D.	10 CFR 35.100, 35.200, and 35.500.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

13-09788-01

Docket or Reference Number

030-01642

Amendment No. 59

Timothy J. Lach, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Alexander Boutselis, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Paul E. Gandy, M.D.	10 CFR 35.100, 35.200 and 35.300.
William J. Miller, M.D.	10 CFR 35.100, 35.200, and 35.300.
Paul DesRosiers, M.D.	10 CFR 35.400.
Loubna T. Scally, M.D.	10 CFR 35.400
Michael F. Busch, M.D.	10 CFR 35.100 and 35.200.
<b>Shamin Dada, M.D.</b>	<b>10 CFR 35.100, 35.200, and 35.300.</b>


13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application August 29, 2003; and
- B. Letters dated November 25, 2003 and February 26, 2004.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

AUG 11 2008

By

  
James R. Mullauer, M.H.S.  
Materials Licensing Branch  
Region III